Clinical Trials


  • The front entrance of the Food And Drug Administration headquarters building.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA panel backs Alnylam drug despite doubts over benefit

    “There is a light wind for benefit, and no wind for risk,” said one adviser who voted with eight others to recommend the biotech’s drug Onpattro for cardiomyopathy of ATTR amyloidosis.

    By Updated Sept. 14, 2023
  • A photo of a declining stock price.
    Image attribution tooltip
    Leonid Sorokin via Getty Images
    Image attribution tooltip
    Emerging biotech

    After IPO success, Acelyrin hits trial setback with inflammation drug

    Acelyrin’s share value collapsed Tuesday after its lead drug fell short in the company’s first big trial test since it raised $540 million in a May IPO.

    By Kristin Jensen • Sept. 12, 2023
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • Image attribution tooltip
    Jonathan Gardner / BioPharma Dive
    Image attribution tooltip

    Daiichi Sankyo, with new data, to seek FDA approval of lung cancer drug

    The HER3-targeting treatment could become the next antibody-drug conjugate to emerge from Daiichi Sankyo’s laboratories, after the AstraZeneca-partnered Enhertu.

    By Sept. 11, 2023
  • Blue and red pill capsules scattered on a table
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    In advocates’ push for superbug funding, ‘$6 billion is nothing’

    The PASTEUR Act could be heading for another setback, but advocates say they see a future for funding research into antimicrobial resistance.

    By Karissa Waddick • Sept. 8, 2023
  • Image attribution tooltip
    Alnylam Pharmaceuticals
    Image attribution tooltip

    Alnylam says hypertension drug succeeded in mid-stage study

    The trial found two higher doses of Alynlam’s RNAi therapy lowered blood pressure better than placebo. But analysts say results from a different study will be more important for the drug’s future.

    By Sept. 7, 2023
  • A  3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Wave readies clinical testing for first RNA editing therapy

    The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.

    By Kristin Jensen • Updated Sept. 5, 2023
  • Illustration of lung cancer
    Image attribution tooltip
    SciePro via Getty Images
    Image attribution tooltip

    Roche claims study success for targeted drug in early lung cancer

    The Swiss pharma said, without details, that it observed “unprecedented” results that could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.

    By Sept. 1, 2023
  • An illustration of necrotic muscle fiber in Duchenne muscular dystrophy.
    Image attribution tooltip
    Jose Luis Calvo Martin, Jose Enrique Garcia-Maurino Muzquiz via Getty Images
    Image attribution tooltip

    FibroGen’s Duchenne drug fails second trial in latest study setback

    The failure marks another Phase 3 miss for the drug, pamrevlumab, and follows a restructuring and CEO switch for the struggling biotech.

    By Aug. 30, 2023
  • Bayer reports positive early data for Parkinson’s cell therapy

    The treatment, developed by a biotech Bayer acquired in 2019, appeared safe in a small trial and showed signs of an effect on disease progression. 

    By Aug. 28, 2023
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck kicks off Phase 3 tests for PCSK9 cholesterol pill

    The company plans to enroll roughly 17,000 people in three Phase 3 trials of the drug, including a large cardiovascular study set to begin later this year.

    By Aug. 25, 2023
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo, with new data, builds case for using Wegovy to protect heart health

    After trial results showed the obesity drug can prevent heart attacks, the company now has data indicating it can help people with heart failure, too.

    By Aug. 25, 2023
  • A medical Illustration showing lung cancer or bronchial carcinoma.
    Image attribution tooltip
    Mohammed Haneefa Nizamudeen via Getty Images
    Image attribution tooltip

    Roche’s surprise study results spur new optimism for TIGIT drugs

    Data inadvertently published from a closely watched lung cancer study suggest a drug blocking the protein TIGIT may help extend survival, a finding that boosted shares of other developers. 

    By Aug. 23, 2023
  • A 3D illustration of sickle cell anemia disease blood cells
    Image attribution tooltip
    Stock/Ezume Images via Getty Images
    Image attribution tooltip

    Fulcrum rejoins sickle cell drug race as FDA lifts study hold

    The biotech, which aims to develop an alternative to existing medicines and emerging gene-based treatments, will focus further testing on sicker patients.

    By Aug. 22, 2023
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    FDA partially halts leukemia studies of Gilead cancer drug

    The hold is the latest setback for a drug that was the center of Gilead’s $5 billion acquisition of biotech Forty Seven in 2020.

    By Aug. 21, 2023
  • A pharmacist prepares to administer COVID-19 vaccine booster shots on September 09, 2022 in Chicago, Illinois.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Moderna builds case for updated COVID shot ahead of latest booster push

    But the demand for booster shots ahead of an expected surge of infections this fall remains an unanswered question weighing heavily on Moderna’s future outlook. 

    By Aug. 18, 2023
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip

    Merck says drug acquired in $1B buyout scores in large kidney cancer study

    The treatment, which Merck picked up through a 2019 acquisition of Peloton Therapeutics, helped delay disease progression in patients with advanced renal cell carcinoma. 

    By Aug. 18, 2023
  • Obesity drugs

    Boehringer moves Wegovy competitor into late-stage testing

    The German pharmaceutical company is launching three Phase 3 trials of an obesity drug called survodutide, which like Wegovy targets the GLP-1 receptor

    By Aug. 17, 2023
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead antibody drug shows signs of potential in early lung cancer

    A combination of Trodelvy and Merck’s Keytruda appears active against lung tumors, but has a high bar to clear and faces competition from AstraZeneca and Daiichi Sankyo.

    By Aug. 17, 2023
  • A sign for the Food and Drug Administration is seen on July 20, 2020 in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA lifts hold on Arcellx’s Gilead-partnered cancer cell therapy

    The agency had paused testing after a patient death, but is now permitting more types of bridging treatment to help keep participants’ disease at bay.

    By Aug. 15, 2023
  • A micrograph of acute myeloid leukemic cells
    Image attribution tooltip
    Jarun011 via Getty Images
    Image attribution tooltip

    A biotech scraps two cancer trials in latest setback for emerging drug class

    ALX Oncology’s decision to end studies in leukemia and myelodysplastic syndrome follows a similar setback from Gilead and casts further doubt on drugs known as CD47 inhibitors.

    By Aug. 11, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis says drug helps control chronic hives in studies

    The studies are another example of drugmakers exploring how so-called BTK inhibitors can be used to treat diseases outside of blood cancer. 

    By Kristin Jensen • Aug. 9, 2023
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo obesity drug protects heart health in large trial

    Treatment with Wegovy led to a 20% reduction in the relative risk of cardiovascular complications or death, a finding that could further shift how doctors treat obesity.

    By Updated Aug. 8, 2023
  • Abstract Structure Background Gold Molecule Or Atom,3d rendering.
    Image attribution tooltip

    onimate/Shutterstock.com

    Image attribution tooltip
    Sponsored by Pearson

    How the right technology and tools can accelerate progress in rare disease clinical trials

    The need for more research into rare diseases is clear, but researchers face significant challenges. Fortunately, technology has created opportunities to innovate in clinical trials for rare diseases.

    Aug. 7, 2023
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    Amgen says KRAS drug met goal in late-stage colon cancer trial

    The company disclosed the study result alongside second quarter earnings showing Lumakras sales were flat versus the same period one year prior.

    By Aug. 3, 2023
  • Electron microscope image of T regulatory cells interacting with antigen-presenting cells
    Image attribution tooltip
    NIAID. (2019). "T Regulatory Cells" [Microscope image]. Retrieved from Flickr.
    Image attribution tooltip
    Emerging biotech

    Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy

    A treatment licensed from the NIH and in clinical testing for lupus is the startup’s lead program, while its founding “Treg” cell therapy research matures, according to CEO Peter Maag.

    By Aug. 3, 2023